Cullgen (shanghai),inc
Clinical trials sponsored by Cullgen (shanghai),inc, explained in plain language.
-
New pill targets rare gene mutations in Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests an experimental drug, CG001419, in adults with advanced solid tumors that have specific NTRK gene changes. The goal is to find a safe dose and see if the drug can shrink tumors. About 42 participants will take the drug by mouth until their disease get…
Phase: PHASE1, PHASE2 • Sponsor: Cullgen (Shanghai),Inc • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for tough blood cancers: experimental drug CG009301 enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called CG009301 in adults with blood cancers (like leukemia or MDS) that returned or didn't respond to standard treatments. The main goals are to find a safe dose and check for side effects. About 45 participants will receive the drug until…
Phase: PHASE1 • Sponsor: Cullgen (Shanghai),Inc • Aim: Disease control
Last updated May 13, 2026 16:00 UTC